Doravirine

Phase 3

MERCK (MRK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in HIV-1

GILDislatravir + lenacapavir

View Full Landscape

Drug Information

Target Indication

HIV-1

Clinical Trial

NCT02275780

Last updated: 12/18/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA11/22/2018

Pifeltro

Pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with HIV 1 without past or present evidence of resistance to the NNRTI class.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

MK-8748Phase 3

Diabetic Retinopathy

alendronate with cholecalciferolPhase 3

Osteoporosis